The DOI matches its Crossref record; 167 of the 167 references it cites were found in a registry or an index.
Anti-EGFR Therapy in Metastatic Colorectal Cancer: Identifying, Tracking, and Overcoming Resistance
Open accessAbstract
Epidermal growth factor receptor (EGFR) inhibitors remain a cornerstone in the treatment of metastatic colorectal cancer with RAS and BRAF wild-type cancer. Yet, primary and acquired resistance limit their benefit for many patients. A growing body of evidence reveals that resistance is not random but rather driven by a complex network of molecular alterations that sustain tumor growth independent of EGFR signaling. These include amplification of ERBB2 (HER2) and MET, activation of the PI3K and AKT pathways, EGFR extracellular domain mutations, and rare kinase fusions. The concept of negative hyperselection has emerged as a powerful strategy to refine patient selection by excluding tumors with these resistance drivers. Multiple clinical trials have consistently shown that patients who are hyperselected based on comprehensive molecular profiling achieve significantly higher response rates and improved survival compared to those selected by RAS and BRAF status alone. Liquid biopsy through circulating tumor DNA has further transformed this landscape, offering a noninvasive tool to capture tumor heterogeneity, monitor clonal evolution in real time, and guide rechallenge strategies after resistance emerges. Together, negative hyperselection, ctDNA-guided monitoring, and emerging therapeutics define a precision-oncology framework for identifying, tracking, and overcoming resistance to anti-EGFR therapy in mCRC, moving the field toward more effective and individualized care. Looking ahead, the development of innovative therapeutics such as bispecific antibodies, antibody drug conjugates, and RNA-based therapies promises to further expand in this challenging clinical scenario. These advances move precision oncology in colorectal cancer from concept to clinical reality, reshaping the standard of care through molecular insights.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“HER2 amplification activates the MEK-ERK (MAPK) and PI3K-AKT pathways, rendering EGFR signal blockade irrelevant [10].”
From Overcoming Resistance to Anti-EGFR Therapies: Mechanisms of Cetuximab and Panitumumab Resistance and Emerging Combination Strategies (2026) · cites this paper as [10]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“PTEN deficiency has been reported in approximately 20–40% of patients with mCRC; however, variability in assessment methods and the lack of standardized testing have limited its implementation as a routine predictive biomarker [10,17].”
From Overcoming Resistance to Anti-EGFR Therapies: Mechanisms of Cetuximab and Panitumumab Resistance and Emerging Combination Strategies (2026) · cites this paper as [10]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“More resent trials, such as the phase III BREAKWATER trial (2024–2025), demonstrated that combination strategy of (a) encorafenib and cetuximab along with (b) chemotherapy, such as mFOLFOX6, has greatly improved the response rate and survival outcomes, supporting a shift toward biomarker-driven combination strategies in the first-line setting [10,73,74].”
From Overcoming Resistance to Anti-EGFR Therapies: Mechanisms of Cetuximab and Panitumumab Resistance and Emerging Combination Strategies (2026) · cites this paper as [10]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“HER2 amplification occurs in approximately 2–5% of all mCRC cases; however, its frequency can rise up to ten to fifteen percent in the RAS wild-type population [10].”
From Overcoming Resistance to Anti-EGFR Therapies: Mechanisms of Cetuximab and Panitumumab Resistance and Emerging Combination Strategies (2026) · cites this paper as [10]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, there are several limitations, such as standardization, assay performance, economic feasibility, limited tumor shedding, restricted access to the bloodstream, and false negatives due to low shedding [10,83,84].”
From Overcoming Resistance to Anti-EGFR Therapies: Mechanisms of Cetuximab and Panitumumab Resistance and Emerging Combination Strategies (2026) · cites this paper as [10]
Experimental — accuracy not yet measured
5 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Colorectal cancer statistics, 2023
Siegel, R. L., Wagle, N. S., Cercek, A., Smith, R. A., & Jemal, A. (2023) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21772 · Cited by 3,733 · cited 1×
“In the United States, the American Cancer Society projects 153,000 new diagnoses and 52,550 for the year 2023, including almost 20,000 cases under the age of fifty [2].”
Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children
Drilon, A., Laetsch, T. W., Kummar, S., DuBois, S. G., Lassen, U. N., Demetri, G. D., Nathenson, M., Doebele, R. C., Farago, A. F., Pappo, A. S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1714448 · Cited by 2,824 · cited 1×
“RET fusions involve the RET (rearranged during transfection) kinase and are targeted by selective RET-inhibitors, including selpercatinib and pralsetinib [105].”
Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer
Roberts, P. J., & Der, C. J. (2007) · Oncogene · doi:10.1038/sj.onc.1210422 · Cited by 2,788 · cited 1×
“These mutations drive resistance to anti-EGFR therapies by constitutively activating the MAPK pathway independent of EGFR-inhibition [92].”
Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways
Wee, P., & Wang, Z. (2017) · Cancers · doi:10.3390/cancers9050052 · Cited by 2,027 · cited 1×
“This arm supports metabolic reprogramming, protein synthesis, and resistance to apoptosis, which are key features of tumor survival [25].”
Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer
Misale, S., Yaeger, R., Hobor, S., Scala, E., Janakiraman, M., Liska, D., Valtorta, E., Schiavo, R., Buscarino, M., Siravegna, G., et al. (2012) · Nature · doi:10.1038/nature11156 · Cited by 1,889 · cited 1×
“Moreover, they may coexist with other genomic alterations that promote the activation of alternative signaling pathways, further compromising the efficacy of the anti-EGFR blockade [131].”
Cervantes, A., Adam, R., Roselló, S., Arnold, D., Normanno, N., Taïeb, J., Seligmann, J., De Baere, T., Osterlund, P., Yoshino, T., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2022.10.003 · Cited by 1,796
The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers
Diaz Jr, L. A., Williams, R. T., Wu, J., Kinde, I., Hecht, J. R., Berlin, J., Allen, B., Bozic, I., Reiter, J. G., Nowak, M. A., et al. (2012) · Nature · doi:10.1038/nature11219 · Cited by 1,713 · cited 1×
“These alterations may arise from the expansion of pre-existing mutated clones or from the emergence of new mutations induced by the selective pressure exerted by prolonged use of agents such as cetuximab or panitumumab [129,130].”
Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients
Siravegna, G., Mussolin, B., Buscarino, M., Corti, G., Cassingena, A., Crisafulli, G., Ponzetti, A., Cremolini, C., Amatu, A., Lauricella, C., et al. (2015) · Nature Medicine · doi:10.1038/nm.3870 · Cited by 1,082 · cited 1×
“In fact, CRC tumor consists of a complex population of distinct cellular clones that, over time, accumulate various genetic and epigenetic alterations, including mutations in oncogenes and tumor suppressor genes, DNA methylation changes, and variations in microRNA expression [122,123].”
Molecular cloning of a new transforming gene from a chemically transformed human cell line
Cooper, C. S., Park, M., Blair, D. G., Tainsky, M. A., Huebner, K., Croce, C. M., & Vande Woude, G. F. (1984) · Nature · doi:10.1038/311029a0 · Cited by 989 · cited 2×
“The PRESSING2 study employed an expanded molecular panel to identify uncommon genomic alterations in RAS wild-type mCRC patients undergoing anti-EGFR therapy [87].”
Mutant PIK3CA promotes cell growth and invasion of human cancer cells.
Samuels, Y., Diaz, L. A., Schmidt-Kittler, O., Cummins, J. M., DeLong, L., Cheong, I., Rago, C., Huso, D. L., Lengauer, C., Kinzler, K. W., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.05.014 · Cited by 915 · cited 1×
“In parallel, alterations in PIK3CA or loss of PTEN hyperac-tivate the AKT pathway, promoting survival and resistance to apoptosis [31,32].”
Cited by
Beyond the membrane: rethinking EGFR signaling in physiology and cancer
Jendrisek, G., Mesa, D., Conte, A., Malabarba, M. G., & Sigismund, S. (2026) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-025-06036-6 · Cited by 18
Agüera-Sánchez, A., Ros, E. P., Martínez‐Martínez, I., & García-Molina, F. (2026) · Journal of Personalized Medicine · doi:10.3390/jpm16010048 · Cited by 9
“It is now firmly established that tumors harboring activating mutations in KRAS or NRAS exon 2, 3, or 4 do not respond to anti-EGFR therapy, because the down-stream signaling is constitutively active [131].”
Clinical trials of bispecific antibody therapy for colorectal cancer: advanced and next steps
Shao, W., Liu, Y., Huang, L., Lu, S., Zhai, Y., Xiong, Y., Chen, N., Ye, P., & Lv, Q. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1758251 · Cited by 6
Nardone, V., Patanè, V., Marinelli, L., D’Ambrosio, L., Tufo, S. D., Chiara, M. D., Brunese, M. C., Rubini, D., Grassi, R., Russo, A., et al. (2025) · Diagnostics · doi:10.3390/diagnostics15222914 · Cited by 5
Abbas, N., Mourad, M., Smaily, H., Al Mahmasani, L., & Shamseddine, A. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27073265 · Cited by 4
“Patients selected through this extended molecular approach will achieve higher response rates and improved clinical outcomes [148].”
Metadata
- Authors
- Leite, L. F., Noronha, M. M., de Menezes, J. S. A., da Conceição, L. D., Almeida, L. F. C., Cappellaro, A. P., Belotto, M., Biachi de Castria, T., Peixoto, R. D., & Megid, T. B. C.
- Affiliations
- Universidade Federal Fluminense (BR)
- Universidade Federal do Ceará (BR)
- Department of Medical Sciences, Universidade Federal da Bahia, Salvador 40170-110, BA, Brazil
- Department of Medical Sciences, Universidade Federal Fluminense, Niteroi 24220-140, RJ, Brazil
- Centro Universitário Maurício de Nassau (BR)
- Department of Surgery, Hospital 9 de Julho, São Paulo 01409-002, SP, Brazil
- Department of Gastrointestinal Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
- BC Cancer Agency (CA)
- Université de Sherbrooke (CA)
- Corresponding author
- Megid, Thais Baccili Cury
- ORCID
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2025-08-27
- Volume
- 17
- Issue
- 17
- Pages
- 2804
- ISSN
- 2072-6694 (ISSN-L)
- PMC
- PMC12427569
- OpenAlex
- W4413757473
- Cited by
- 32
- References
- 159
- Citations by year
- 2026: 26 · 2025: 6
- FWCI
- 3.76
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Cancers (publishedVersion, cc-by)
- PubMed (publishedVersion)
- PubMed Central (publishedVersion, cc-by)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Keywords
- anti-EGFR therapy, metastatic colorectal cancer, EGFR inhibitors, acquired drug resistance, primary resistance, comprehensive molecular profiling, ERBB2 amplification, MET amplification, PI3K/Akt signaling, circulating tumor DNA, liquid biopsy, clonal evolution, precision oncology, bispecific antibodies, antibody-drug conjugates, RNA therapeutics
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Anti-EGFR Therapy in Metastatic Colorectal Cancer: Identifying, Tracking, and Overcoming Resistance. https://app.cochat.ai/papers/10.3390/cancers17172804
- The paper
- Leite, L. F., Noronha, M. M., de Menezes, J. S. A., da Conceição, L. D., Almeida, L. F. C., Cappellaro, A. P., Belotto, M., Biachi de Castria, T., Peixoto, R. D., & Megid, T. B. C. (2025). Anti-EGFR Therapy in Metastatic Colorectal Cancer: Identifying, Tracking, and Overcoming Resistance. Cancers. https://doi.org/10.3390/cancers17172804
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.